Zidovudine
- Generic Name
- Zidovudine
- Brand Names
- Combivir, Retrovir, Trizivir
- Drug Type
- Small Molecule
- Chemical Formula
- C10H13N5O4
- CAS Number
- 30516-87-1
- Unique Ingredient Identifier
- 4B9XT59T7S
- Background
A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by an azido group. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA during reverse transcription. It improves immunologic function, partially reverses the HIV-induced neurological dysfunction, and improves certain other clinical abnormalities associated with AIDS. Its principal toxic effect is dose-dependent suppression of bone marrow, resulting in anemia and leukopenia. [PubChem]
- Indication
Used in combination with other antiretroviral agents for the treatment of human immunovirus (HIV) infections.
- Associated Conditions
- HIV Transmission, Human Immunodeficiency Virus (HIV) Infections, Perinatal HIV transmission
- Associated Therapies
- -
Effectiveness of Anti-HIV Therapy (HAART) in HIV-Infected Patients With Tuberculosis
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2008-09-11
- Target Recruit Count
- 44
- Registration Number
- NCT00004736
- Locations
- 🇺🇸
Univ of California / San Diego Treatment Ctr, San Diego, California, United States
🇺🇸Univ of Southern California / LA County USC Med Ctr, Los Angeles, California, United States
🇺🇸Vanderbilt Univ Med Ctr, Nashville, Tennessee, United States
A Study of Dideoxycytidine Plus Zidovudine in the Treatment of AIDS or Advanced AIDS Related Complex (ARC)
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2008-08-08
- Target Recruit Count
- 68
- Registration Number
- NCT00000978
- Locations
- 🇺🇸
Univ of California / San Diego Treatment Ctr, San Diego, California, United States
🇺🇸Univ of Miami School of Medicine, Miami, Florida, United States
A Phase I Study of the Safety and Pharmacokinetics of Recombinant Human CD4-Immunoglobulin G (rCD4-IgG) Administered by Intravenous Bolus Injection in Combination With Oral Zidovudine in Patients With AIDS and AIDS-Related Complex
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2008-08-06
- Target Recruit Count
- 40
- Registration Number
- NCT00000976
- Locations
- 🇺🇸
Univ of Massachusetts, Worcester, Massachusetts, United States
🇺🇸Univ of California / San Diego Treatment Ctr, San Diego, California, United States
🇺🇸Univ of Miami School of Medicine, Miami, Florida, United States
A Randomized Study of Activity, Safety, and Tolerance of Oral Ro 24-7429 (Tat Antagonist) in Patients With HIV Infection
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2008-08-04
- Target Recruit Count
- 96
- Registration Number
- NCT00000760
- Locations
- 🇺🇸
UCSD, San Diego, California, United States
🇺🇸Case Western Reserve Univ, Cleveland, Ohio, United States
🇺🇸Harvard (Massachusetts Gen Hosp), Boston, Massachusetts, United States
Safety and Efficacy of Polyethylene Glycolated IL-2 (PEG IL-2) Plus Zidovudine in HIV Positive, Asymptomatic and Symptomatic Individuals
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2008-08-04
- Target Recruit Count
- 26
- Registration Number
- NCT00000664
- Locations
- 🇺🇸
Stanford Univ School of Medicine, Stanford, California, United States
The Pharmacokinetics of Zidovudine and Oxazepam Alone and in Combination in the HIV-Infected Patient
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2008-08-04
- Target Recruit Count
- 8
- Registration Number
- NCT00000661
- Locations
- 🇺🇸
Palo Alto Veterans Adm Med Ctr / Stanford Univ, Palo Alto, California, United States
The Safety and Effectiveness of Clarithromycin Plus Zidovudine or Dideoxyinosine in the Treatment of Mycobacterium Avium Complex (MAC) Infections in Children With AIDS
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2008-08-04
- Lead Sponsor
- Abbott
- Target Recruit Count
- 24
- Registration Number
- NCT00000971
- Locations
- 🇺🇸
Children's Hosp of Los Angeles, Los Angeles, California, United States
🇺🇸Natl Cancer Institute / HIV / AIDS Malignancy Branch, Bethesda, Maryland, United States
The Safety and Effectiveness of a Type of Interleukin-2 Plus Zidovudine Plus Thymosin in HIV-Positive Patients With and Without Symptoms of Infection
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2008-07-30
- Target Recruit Count
- 12
- Registration Number
- NCT00001036
- Locations
- 🇺🇸
Stanford Univ Med Ctr, Stanford, California, United States
The Effects of Valproic Acid on Zidovudine Glucuronidation and Pharmacokinetics in HIV-Infected Patients.
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2008-07-30
- Target Recruit Count
- 6
- Registration Number
- NCT00000629
- Locations
- 🇺🇸
Tulane Univ Med School, New Orleans, Louisiana, United States
A Pharmacokinetic Study of L-697,661 Alone and in Combination With Zidovudine
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2008-07-30
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 27
- Registration Number
- NCT00000628
- Locations
- 🇺🇸
Northwestern Univ Med School, Chicago, Illinois, United States
🇺🇸Rush Presbyterian - Saint Luke's Med Ctr, Chicago, Illinois, United States
🇺🇸San Francisco Gen Hosp, San Francisco, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.